Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride key facts

Used for
EXTRANEAL (icodextrin) is indicated for a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
No generic listed by the FDA
Latest FDA recall
None listed

Sources: FDA label (June 30, 2025); FDA NDC Directory (November 13, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride used for?
The FDA-approved label (Extraneal, Vantive US Healthcare LLC, June 30, 2025) says: “EXTRANEAL (icodextrin) is indicated for a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride?
The “Adverse Reactions” section of the FDA label (Extraneal, Vantive US Healthcare LLC, June 30, 2025) begins: “The most common adverse reaction (incidence > 5%) was rash.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride?
The “Drug Interactions” section of the FDA label (Extraneal, Vantive US Healthcare LLC, June 30, 2025) begins: “As with other dialysis solutions, blood concentrations of dialyzable drugs may be reduced by dialysis. Dosage adjustment of concomitant medications may be necessary. In patients using cardiac glycosides (digoxin and others), plasma levels of calcium, potassium and magnesium must be carefully monitored [see Warnings and Precautions (5.6)].” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride?
1 company lists prescription products of Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride in the FDA NDC Directory, including Vantive US Healthcare LLC.

What Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

EXTRANEAL (icodextrin) is indicated for a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy. …

— FDA label: Extraneal, Vantive US Healthcare LLC, effective June 30, 2025. Read the full label on DailyMed →

Label quoted: the one for the most common form (injection, solution, intraperitoneal), Extraneal, Vantive US Healthcare LLC; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The most common adverse reaction (incidence > 5%) was rash.

Read more of this section

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Vantive US Healthcare LLC at 1-855-857-0003 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience EXTRANEAL was originally studied in controlled clinical trials of 493 patients with kidney failure in patients requiring long-term kidney replacement therapy who received a single daily exchange of EXTRANEAL for the long dwell (8-to 16- hours). There were 215 patients exposed for at least 6 months and 155 patients exposed for at least one year. The population was 18-83 years of age, 56% male and 44% female, 73% Caucasian, 18% Black, 4% Asian, 3% Hispanic, and it included patients with the following comorbid conditions: 27% diabetes, 49% hypertension and 23% hypertensive nephropathy. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates. Rash was the most frequently occurring EXTRANEAL-related adverse reaction (5.5%, EXTRANEAL; 1.7% Control). Seven patients on EXTRANEAL discontinued treatment due to rash, and one patient on EXTRANEAL discontinued due to exfoliative dermatitis. The rash typically appeared within the first three weeks of treatment and resolved with treatment discontinuation or, in some patients, with continued treatment. Table 1 shows the adverse events reported in these clinical studies regardless of causality, occurring in ≥ 5% of patients and more common on EXTRANEAL than control. Table 1 - Adverse Experiences in ≥5% of Patients and More Common on EXTRANEAL EXTRANEAL Control N = 493 N = 347 Peritonitis 26% 25% Upper respiratory infection 15% 13% Hypertension 13% 8% Rash 10% 5% Headache 9% 7% Abdominal Pain 8% 6% Flu syndrome 7% 6% Nausea 7% 5% Cough increase 7% 4% Edema 6% 5% Accidental injury 6% 4% Chest pain 5% 4% Dyspepsia 5% 4% Hyperglycemia 5% 4% Clinical Laboratory Findings An increase in mean serum alkaline phosphatase has been observed in clinical studies of ESRD patients receiving EXTRANEAL. No associated increases in other liver chemistry tests were observed. Serum alkaline phosphatase levels did not show progressive increase over a 12-month study period. Levels returned to normal approximately two weeks after discontinuation of EXTRANEAL. Decreases in serum sodium and chloride have been observed in patients using EXTRANEAL.

— FDA label: Extraneal, Vantive US Healthcare LLC, effective June 30, 2025. This is part of the section. Read the full label on DailyMed →

Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

As with other dialysis solutions, blood concentrations of dialyzable drugs may be reduced by dialysis. Dosage adjustment of concomitant medications may be necessary. In patients using cardiac glycosides (digoxin and others), plasma levels of calcium, potassium and magnesium must be carefully monitored [see Warnings and Precautions (5.6)].

Read more of this section

Insulin: Patients with insulin-dependent diabetes may require modification of insulin dosage following initiation of treatment with EXTRANEAL. Monitor blood glucose and adjust insulin, if needed [see Warnings and Precautions (5.1)].

— FDA label: Extraneal, Vantive US Healthcare LLC, effective June 30, 2025. Read the full label on DailyMed →

Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

For intraperitoneal administration only. Not for intravenous or intra-arterial administration. Administer as a single daily peritoneal dialysis (PD) exchange for the long dwell. Dosage should be individualized by the prescribing physician experienced in the treatment of kidney failure in patients requiring long-term kidney replacement therapy with PD. (2.1) 2.1 Basic Dosing Information EXTRANEAL is intended for intraperitoneal administration only.

Read more of this section

Not for intravenous or intra-arterial administration. Administer as a single daily exchange for the long dwell in continuous ambulatory peritoneal dialysis or automated peritoneal dialysis. The recommended dwell time is 8 to 16 hours. Administer over a period of 10 to 20 minutes at a rate that is comfortable for the patient. The mode of therapy, frequency of treatment, exchange volume, duration of dwell, and length of dialysis should be initiated and supervised by the prescribing physician experienced in the treatment of kidney failure in patients requiring long-term kidney replacement therapy with peritoneal dialysis. It is recommended that patients being placed on peritoneal dialysis should be appropriately trained in a program that is under supervision of a physician. 2.2 Directions for Use For complete CAPD and APD system preparation, see directions accompanying ancillary equipment. Aseptic technique should be used throughout the peritoneal dialysis procedure. For single-dose only. Storage Store in moisture barrier overwrap and in carton until ready to use [see How Supplied/Storage and Handling (16)]. Warming For patient comfort, EXTRANEAL can be warmed to 37°C (98.6°F). Only dry heat should be used (e.g., heating pad, warming plate). Do not immerse EXTRANEAL in water for warming. Do not use a microwave oven to warm EXTRANEAL. Do not heat above 40°C (104°F). To Open To open, tear the overwrap down at the slit and remove the solution container. Some opacity of the plastic, due to moisture absorption during the sterilization process, may be observed. This does not affect the solution quality or safety and may often leave a slight amount of moisture within the overwrap. Inspect for Container Integrity and Solution Appearance Do not use EXTRANEAL if it is cloudy or discolored, if it contains particulate matter, or if the container is leaking. Inspect the patient connector to ensure the pull ring is attached. Do not use if pull ring is not attached to the connector. Inspect the EXTRANEAL container for signs of leakage and check for minute leaks by squeezing the container firmly. If the container has frangible(s), inspect that they are positioned correctly and are not broken. Do not use EXTRANEAL if the frangible(s) are broken or leaks are suspected as sterility may be impaired. For EXTRANEAL in ULTRABAG, inspect the tubing and drain container for presence of solution. Small droplets are acceptable, but if solution flows past the frangible prior to use, do not use and discard the units. Adding Medications The decision to add medication should be made by the physician after careful evaluation of the patient [see Drug Interactions (7), Clinical Pharmacology (12.3)].

— FDA label: Extraneal, Vantive US Healthcare LLC, effective June 30, 2025. This is part of the section. Read the full label on DailyMed →

Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary EXTRANEAL is a pharmacologically inactive solution. While there are no adequate and well controlled studies in pregnant women, appropriate administration of EXTRANEAL with monitoring of hematology, blood chemistry, and fluid status is not expected to cause fetal harm. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.

Read more of this section

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

— FDA label: Extraneal, Vantive US Healthcare LLC, effective June 30, 2025. Read the full label on DailyMed →

When Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

EXTRANEAL is contraindicated in patients with:

  • known hypersensitivity to icodextrin [see Warnings and Precautions (5.3)]
  • maltose or isomaltose intolerance
  • glycogen storage disease
  • severe lactic acidosis, as EXTRANEAL contains lactate which may contribute to worsening acidosis if conversion to bicarbonate is impaired and may be associated with hyperventilation, lethargy, hypotension or irregular heart rhythms.
Read more of this section
  • Known hypersensitivity to icodextrin
  • Maltose or isomaltose intolerance
  • Glycogen storage disease
  • Pre-existing severe lactic acidosis

— FDA label: Extraneal, Vantive US Healthcare LLC, effective June 30, 2025. Read the full label on DailyMed →

Icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

No clinical trial data are available on experiences of overdosage with EXTRANEAL. Overdosage of EXTRANEAL would be expected to result in higher levels of serum icodextrin and metabolites, but it is not known what signs or symptoms might be caused by exposure in excess of the exposures used in clinical trials. An increase in plasma osmolality or clinical manifestations of hypovolemia may occur.

Read more of this section

In the event of overdosage with EXTRANEAL, continued peritoneal dialysis with glucose-based solutions should be provided.

— FDA label: Extraneal, Vantive US Healthcare LLC, effective June 30, 2025. Read the full label on DailyMed →

Forms and how it is given

Dosage formsInjection, solution
RouteIntraperitoneal
Prescription products1 in the FDA NDC Directory
Brand namesExtraneal

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA021321
EXTRANEAL
Vantive Us HlthcareDecember 20, 2002 18, latest April 22, 2024
2024: Labeling · 2019: REMS · 2016: Labeling

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)1100742, 1100746
SPL set ID of the quoted labeld5b85158-b0d6-4855-9d07-8d1b3ad9ab71
FDA labels (SPL)1
FDA applicationsNDA021321
Active ingredients (FDA)CALCIUM CHLORIDE / ICODEXTRIN / MAGNESIUM CHLORIDE / SODIUM CHLORIDE / SODIUM LACTATE

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Extraneal, Vantive US Healthcare LLC, effective June 30, 2025; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers